MXCT
MaxCyte, Inc. NASDAQ$0.86
Mkt Cap $91.7M
52w Low $0.64
9.7% of range
52w High $2.86
50d MA $0.79
200d MA $1.32
P/E (TTM)
-2.1x
EV/EBITDA
-4.2x
P/B
0.6x
Debt/Equity
0.1x
ROE
-26.0%
P/FCF
-4.6x
RSI (14)
—
ATR (14)
—
Beta
1.45
50d MA
$0.79
200d MA
$1.32
Avg Volume
1.1M
About
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.08 | -0.06 | +25.0% | 0.74 | -1.4% | -6.8% | -3.1% | -7.6% | -8.6% | -5.1% | — |
| Nov 12, 2025 | AMC | -0.11 | -0.12 | -9.1% | 1.58 | -3.8% | -4.4% | +0.0% | +3.2% | +8.2% | +7.6% | — |
| Aug 6, 2025 | AMC | -0.10 | -0.12 | -20.0% | 2.04 | -16.7% | -29.9% | -32.4% | -35.3% | -37.7% | -32.4% | — |
| May 7, 2025 | AMC | -0.10 | -0.10 | +0.0% | 2.74 | -10.6% | -11.3% | -13.9% | -17.2% | -19.7% | -19.7% | — |
| Mar 11, 2025 | AMC | -0.12 | -0.10 | +16.7% | 3.47 | -10.4% | -8.4% | -11.8% | -5.2% | -6.1% | -8.1% | — |
| Nov 6, 2024 | AMC | -0.13 | -0.11 | +15.4% | 3.88 | +3.4% | -10.8% | -12.6% | -7.7% | -8.8% | -8.5% | — |
| Aug 6, 2024 | AMC | -0.14 | -0.09 | +35.7% | 4.45 | +4.0% | -8.3% | -6.1% | -6.1% | -9.4% | -9.2% | — |
| May 7, 2024 | AMC | -0.14 | -0.09 | +35.7% | 3.93 | +0.3% | +18.1% | +20.4% | +20.6% | +19.8% | +15.5% | — |
| Mar 12, 2024 | AMC | -0.10 | -0.05 | +50.0% | 3.98 | +1.8% | +4.5% | +5.5% | +8.3% | +4.8% | +12.1% | — |
| Nov 8, 2023 | AMC | -0.10 | -0.11 | -10.0% | 3.35 | -3.0% | -3.3% | -1.8% | +3.9% | +10.7% | +11.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Craig-Hallum | Maintains | Buy → Buy | — | $0.74 | $0.73 | -1.4% | -6.8% | -3.1% | -7.6% | -8.6% | -5.1% |
| Aug 11 | BTIG | Downgrade | Buy → Neutral | — | $1.38 | $1.36 | -1.4% | -4.3% | -8.0% | +0.0% | +2.2% | -1.4% |
| Aug 7 | William Blair | Downgrade | Outperform → Market Perform | — | $2.04 | $1.70 | -16.7% | -29.9% | -32.4% | -35.3% | -37.7% | -32.4% |
| Mar 12 | Stifel | Maintains | Buy → Buy | — | $3.47 | $3.11 | -10.4% | -8.4% | -11.8% | -5.2% | -6.1% | -8.1% |
| Apr 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.96 | $3.97 | +0.3% | -4.0% | -5.6% | -6.8% | -6.3% | -7.6% |
| Mar 13 | BTIG | Maintains | Buy → Buy | — | $3.98 | $4.05 | +1.8% | +4.5% | +5.5% | +8.3% | +4.8% | +12.1% |
| Mar 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.98 | $4.05 | +1.8% | +4.5% | +5.5% | +8.3% | +4.8% | +12.1% |
| Oct 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.27 | $2.53 | -22.6% | -20.5% | -12.5% | -8.0% | -6.4% | -8.6% |
| Mar 28 | Stephens & Co. | Maintains | Overweight → Overweight | — | $4.11 | $4.12 | +0.2% | -0.7% | +7.3% | +14.4% | +20.4% | +16.5% |
| Aug 15 | BTIG | Maintains | Buy → Buy | — | $5.87 | $5.85 | -0.3% | -2.0% | +5.1% | +2.2% | +1.5% | -4.3% |
Recent Filings
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A leadership transition to a new CFO effective March 30, 2026 signals potential strategic shifts in financial management and capital allocation that investors should monitor for signs of operational changes or guidance updates.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate 8-K/FD disclosure suggests MXCT shared non-material information with investors that won't trigger liability, indicating no significant news requiring incorporation into formal filings.
Mar 24
8-K
Unknown — 8-K Filing
Maxcyte faces delisting risk from Nasdaq unless its stock price recovers above minimum bid requirements, threatening market access and investor confidence.
Mar 20
Data updated apr 26, 2026 1:59pm
· Source: massive.com